DualChip^® microarray as a new tool in cancer research

References

• Jemal A, Siegel R, Ward E. Cancer statistics, 2006. CA Cancer J. Clin.56, 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ. Mol. Mutagen.39, 82–88 (2002).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Zammatteo N, Remacle J, Leclercq G. A low-density DNA microarray for analysis of markers in breast cancer. Int. J. Biol. Markers17, 5–23 (2002).
   PubMedGoogle Scholar
• Valavaara R. Reliability of estrogen receptors in predicting response to antiestrogens. Oncology (Williston Park)11, 14–18 (1997).
   PubMedGoogle Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol.23, 1147–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol.182, 150–162 (2000).
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol.14, 737–744 (1996).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17, 2639–2648 (1999).
   PubMed Web of Science ®Google Scholar
• Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology61(Suppl. 2), 14–21 (2001).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Look MP, Foekens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS107, 150–159 (1999).
   PubMedGoogle Scholar
• Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J. Pathol.205, 275–292 (2005).
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer2, 48–58 (2002).
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature Rev. Drug Discov.5, 219–234 (2006).
   PubMed Web of Science ®Google Scholar
• Schuierer MM, Langmann T. Molecular diagnosis of ATP-binding cassette transporter-related diseases. Expert Rev. Mol. Diagn.5, 755–767 (2005).
   PubMed Web of Science ®Google Scholar
• Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia14, 467–473 (2000).
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int. J. Clin. Pharmacol. Ther.38, 94–110 (2000).
   PubMed Web of Science ®Google Scholar
• Marie JP. Drug resistance in hematologic malignancies. Curr. Opin. Oncol.13, 463–469 (2001).
   PubMed Web of Science ®Google Scholar
• Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br. J. Haematol.128, 324–332 (2005).
   PubMed Web of Science ®Google Scholar
• van der Kolk DM, de Vries EG, Muller M, Vellenga, E. The role of drug efflux pumps in acute myeloid leukemia. Leuk. Lymphoma43, 685–701 (2002).
   PubMed Web of Science ®Google Scholar
• Steinbach D, Furchtbar S, Sell W et al. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia17, 470–471 (2003).
   PubMed Web of Science ®Google Scholar
• Sievers EL, Smith FO, Woods WG et al. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Leukemia9, 2042–2048 (1995).
   PubMedGoogle Scholar
• Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin. Cancer Res.9, 1083–1086 (2003).
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat AM, Sayada L et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res.10, 7896–7902 (2004).
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat AM, Sayada L et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin. Cancer Res.11, 7764–7772 (2005).
   PubMed Web of Science ®Google Scholar
• Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia16, 1443–1447 (2002).
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Del Poeta G Maurillo L et al. P-glycoprotein and Bcl-2 levels predict outcome in adult acute lymphoblastic leukaemia. Br. J. Haematol.121, 730–738 (2003).
   PubMed Web of Science ®Google Scholar
• Plasschaert SL, Vellenga E, de Bont ES et al. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk. Lymphoma44, 85–95 (2003).
   PubMed Web of Science ®Google Scholar
• Tafuri A, Gregorj C, Petrucci MT et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood100, 974–981 (2002).
   PubMed Web of Science ®Google Scholar
• Plasschaert SL, van der Kolk DM, de Bont ES et al. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin. Cancer Res.9, 5171–5177 (2003).
   PubMed Web of Science ®Google Scholar
• Plasschaert SL, de Bont ES, Boezen M et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin. Cancer Res.11, 8661–8668 (2005).
   PubMed Web of Science ®Google Scholar
• Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer10, 43–73 (2003).
   PubMed Web of Science ®Google Scholar
• Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J. Natl Cancer Inst.81, 696–701 (1989).
   PubMed Web of Science ®Google Scholar
• Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br. J. Cancer60, 815–818 (1989).
   PubMed Web of Science ®Google Scholar
• Burger H, Foekens JA, Look MP et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res.9, 827–836 (2003).
   PubMed Web of Science ®Google Scholar
• Kafka A, Sauer G, Jaeger C et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol.22, 1117–1121 (2003).
   PubMed Web of Science ®Google Scholar
• Zochbauer-Muller S, Filipits M, Rudas M et al. P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res.21, 119–124 (2001).
   PubMedGoogle Scholar
• Kanzaki A, Toi M, Nakayama K et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn. J. Cancer Res.92, 452–458 (2001).
   PubMedGoogle Scholar
• Ito K, Fujimori M, Nakata S et al. Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol. Res.10, 99–109 (1998).
   PubMed Web of Science ®Google Scholar
• Filipits M, Pohl G, Rudas M et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol.23, 1161–1168 (2005).
   PubMed Web of Science ®Google Scholar
• Rudas M, Filipits M, Taucher S et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res. Treat.81, 149–157 (2003).
   PubMed Web of Science ®Google Scholar
• Faneyte IF, Kristel PM, van de Vijver MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res.24, 2931–2939 (2004).
   PubMed Web of Science ®Google Scholar
• Faneyte IF, Kristel PM, Maliepaard M et al. Expression of the breast cancer resistance protein in breast cancer Clin. Cancer Res.8, 1068–1074 (2002).
   Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA101, 14228–14233 (2004).
   PubMed Web of Science ®Google Scholar
• Norwood K, Wang RY, Hirschmann-Jax C et al. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk. Res.28, 295–299 (2004).
   PubMedGoogle Scholar
• Wulf GG, Modlich S, Inagaki N et al. ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica89, 1395–1397 (2004).
   PubMedGoogle Scholar
• Yasui K, Mihara S, Zhao C et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res.64, 1403–1410 (2004).
   PubMed Web of Science ®Google Scholar
• Langmann T, Mauerer R, Schmitz G. Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin. Chem.52, 310–313 (2006).
   PubMed Web of Science ®Google Scholar
• Langmann T, Mauerer R, Zahn A et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin. Chem.49, 230–238 (2003).
   PubMed Web of Science ®Google Scholar
• Szakacs G, Annereau JP, Lababidi S et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell6, 129–137 (2004).
   PubMed Web of Science ®Google Scholar
• Annereau JP, Szakacs G, Tucker CJ et al. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol. Pharmacol.66, 1397–1405 (2004).
   PubMed Web of Science ®Google Scholar
• Gillet JP, Efferth T, Steinbach D et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res.64, 8987–8993 (2004).
   PubMed Web of Science ®Google Scholar
• Huang Y, Anderle P, Bussey K J et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res.64, 4294–4301 (2004).
   PubMed Web of Science ®Google Scholar
• Liu Y, Peng H, Zhang JT. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol. Pharmacol.68, 430–438 (2005).
   PubMed Web of Science ®Google Scholar
• de Longueville F, Surry D, Meneses-Lorente G et al. Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray. Biochem. Pharmacol.64, 137–149 (2002).
   PubMed Web of Science ®Google Scholar
• Kerr MK, Churchill GA. Experimental design for gene expression microarrays. Biostatistics2, 183–201 (2001).
   PubMedGoogle Scholar
• Simon R, Radmacher MD, Dobbin K. Design of studies using DNA microarrays. Genet. Epidemiol.23, 21–36 (2002).
   PubMed Web of Science ®Google Scholar
• Quackenbush J. Microarray data normalization and transformation. Nature Genet.32(Suppl.), 496–501 (2002).
   PubMed Web of Science ®Google Scholar
• Gillet JP, Schneider J, Bertholet V, de Longueville F, Remacle J, Efferth T. Microarray expression profiling of ABC transporters in human breast cancer. Cancer Genomics Proteomics (2006) (In Press).
   PubMedGoogle Scholar
• de Longueville F, Atienzar F A, Marcq L et al. Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol. Sci.75, 378–392 (2003).
   PubMed Web of Science ®Google Scholar
• de Magalhaes JP, Chainiaux F, de Longueville F et al. Gene expression and regulation in H2O2-induced premature senescence of human foreskin fibroblasts expressing or not telomerase. Exp. Gerontol.39, 1379–1389 (2004).
   PubMed Web of Science ®Google Scholar
• Debacq-Chainiaux F, Borlon C, Pascal T et al. Repeated exposure of human skin fibroblasts to UVB at subcytotoxic level triggers premature senescence through the TGF-β1 signaling pathway. J. Cell Sci.118, 743–758 (2005).
   PubMedGoogle Scholar
• de Longueville F, Lacroix M, Barbuto AM et al. Molecular characterization of breast cancer cell lines by a low-density microarray. Int. J. Oncol.27, 881–892 (2005).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat.83, 249–289 (2004).
   PubMed Web of Science ®Google Scholar
• Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res. Treat.31, 325–335 (1994).
   PubMed Web of Science ®Google Scholar
• Perou CM, Jeffrey SS, van de Rijn M et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl Acad. Sci. USA96, 9212–9217 (1999).
   PubMed Web of Science ®Google Scholar
• Borras M, Lacroix M, Legros N, Leclercq G. Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. Cancer Lett.120, 23–30 (1997).
   PubMedGoogle Scholar
• Siwek B, Larsimont D, Lacroix M, Body JJ. Establishment and characterization of three new breast-cancer cell lines. Int. J. Cancer76, 677–683 (1998).
   PubMedGoogle Scholar
• Jarvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol.156, 839–847 (2000).
   PubMed Web of Science ®Google Scholar
• Kauraniemi P, Barlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res.61, 8235–8240 (2001).
   PubMed Web of Science ®Google Scholar
• Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol.158, 207–214 (2001).
   PubMed Web of Science ®Google Scholar
• Myal Y, Iwasiow B, Cosby H et al. Analysis of tissue- and hormone-specific regulation of the human prolactin-inducible protein/gross cystic disease fluid protein-15 gene in transgenic mice. J. Mol. Endocrinol.21, 217–223 (1998).
   PubMed Web of Science ®Google Scholar
• Ormandy CJ, Clarke CL, Kelly PA, Sutherland RL. Androgen regulation of prolactin-receptor gene expression in MCF-7 and MDA-MB-453 human breast cancer cells. Int. J. Cancer50, 777–782 (1992).
   PubMedGoogle Scholar
• Peirce SK, Chen WY, Chen WY. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J. Endocrinol.171, R1–R4 (2001).
   Google Scholar
• Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet.24, 236–244 (2000).
   PubMed Web of Science ®Google Scholar
• Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science306, 640–643 (2004).
   PubMed Web of Science ®Google Scholar
• Hwang D, Rust AG, Ramsey S et al. A data integration methodology for systems biology. Proc. Natl Acad. Sci. USA102, 17296–17301 (2005).
   PubMed Web of Science ®Google Scholar
• Hwang D, Smith JJ, Leslie DM et al. A data integration methodology for systems biology: experimental verification. Proc. Natl Acad. Sci. USA102, 17302–17307 (2005).
   PubMed Web of Science ®Google Scholar